Guggenheim Maintains Buy on ArriVent BioPharma, Raises Price Target to $30
Benzinga Newsdesk 5 days ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $18 to $30.
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $18 to $30.